Coherus BioSciences (CHRS) Competitors $0.85 -0.05 (-5.88%) Closing price 04:00 PM EasternExtended Trading$0.87 +0.02 (+2.23%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. SLDB, GLUE, ERAS, MREO, SNDL, TRDA, SIGA, ETON, KMDA, and ALLOShould you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Solid Biosciences (SLDB), Monte Rosa Therapeutics (GLUE), Erasca (ERAS), Mereo BioPharma Group (MREO), SNDL (SNDL), Entrada Therapeutics (TRDA), SIGA Technologies (SIGA), Eton Pharmaceuticals (ETON), Kamada (KMDA), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry. Coherus BioSciences vs. Solid Biosciences Monte Rosa Therapeutics Erasca Mereo BioPharma Group SNDL Entrada Therapeutics SIGA Technologies Eton Pharmaceuticals Kamada Allogene Therapeutics Coherus BioSciences (NASDAQ:CHRS) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking. Do insiders and institutionals have more ownership in CHRS or SLDB? 72.8% of Coherus BioSciences shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 7.6% of Coherus BioSciences shares are owned by company insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend CHRS or SLDB? Coherus BioSciences presently has a consensus target price of $5.38, indicating a potential upside of 531.61%. Solid Biosciences has a consensus target price of $15.67, indicating a potential upside of 258.50%. Given Coherus BioSciences' higher probable upside, research analysts plainly believe Coherus BioSciences is more favorable than Solid Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 4 Strong Buy rating(s) 3.33 Does the MarketBeat Community prefer CHRS or SLDB? Coherus BioSciences received 174 more outperform votes than Solid Biosciences when rated by MarketBeat users. However, 69.27% of users gave Solid Biosciences an outperform vote while only 65.36% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformCoherus BioSciencesOutperform Votes44965.36% Underperform Votes23834.64% Solid BiosciencesOutperform Votes27569.27% Underperform Votes12230.73% Is CHRS or SLDB more profitable? Solid Biosciences has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Coherus BioSciences-0.15% N/A -24.44% Solid Biosciences N/A -58.75%-47.84% Which has higher valuation and earnings, CHRS or SLDB? Solid Biosciences has lower revenue, but higher earnings than Coherus BioSciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus BioSciences$266.96M0.37-$237.89M$0.194.48Solid Biosciences$8.09M41.86-$96.01M-$3.04-1.44 Which has more volatility and risk, CHRS or SLDB? Coherus BioSciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Does the media refer more to CHRS or SLDB? In the previous week, Coherus BioSciences had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Coherus BioSciences and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.10 beat Coherus BioSciences' score of 0.47 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySolid Biosciences beats Coherus BioSciences on 12 of the 19 factors compared between the two stocks. Remove Ads Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.63M$3.03B$5.65B$8.06BDividend YieldN/A1.54%4.56%4.02%P/E Ratio-10.6429.3124.6019.02Price / Sales0.37435.98383.6393.16Price / CashN/A168.6838.1634.64Price / Book-0.493.956.944.34Net Income-$237.89M-$71.95M$3.20B$247.06M7 Day Performance-10.08%-4.54%-2.30%-0.52%1 Month Performance-21.20%-9.31%3.06%-3.72%1 Year Performance-64.83%-25.71%11.11%1.81% Coherus BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus BioSciences3.6304 of 5 stars$0.85-5.9%$5.38+531.6%-60.7%$104.79M$266.96M-10.64330SLDBSolid Biosciences3.571 of 5 stars$5.36+5.3%$15.67+192.3%-68.6%$415.36M$8.09M-1.76100GLUEMonte Rosa Therapeutics2.9902 of 5 stars$6.73+7.3%$15.25+126.6%-16.7%$413.47M$14.98M-3.6890Earnings ReportShort Interest ↓Analyst RevisionERASErasca3.6638 of 5 stars$1.46+1.4%$4.90+235.6%-25.3%$412.78MN/A-1.76120Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMREOMereo BioPharma Group2.4255 of 5 stars$2.63+0.4%$7.83+197.8%-19.7%$408.03M$1M0.0040Earnings ReportAnalyst ForecastNews CoverageGap UpSNDLSNDL3.6434 of 5 stars$1.55+2.6%$3.25+109.7%-24.4%$407.30M$911.22M-5.002,516TRDAEntrada Therapeutics3.0141 of 5 stars$10.81flat$25.67+137.4%-28.1%$406.40M$210.78M6.80110SIGASIGA Technologies2.5436 of 5 stars$5.63+0.9%N/A-31.1%$402.19M$138.72M4.6940Positive NewsETONEton Pharmaceuticals2.7885 of 5 stars$15.29-1.9%$24.00+57.0%+251.2%$398.32M$34.68M-69.5020Short Interest ↓KMDAKamada3.5729 of 5 stars$6.80-5.3%$14.50+113.2%+23.4%$390.86M$160.95M24.29360Analyst DowngradeShort Interest ↑Gap DownHigh Trading VolumeALLOAllogene Therapeutics3.0562 of 5 stars$1.85-4.6%$9.40+408.1%-62.7%$387.89M$22,000.00-1.19310Gap Up Remove Ads Related Companies and Tools Related Companies Solid Biosciences Alternatives Monte Rosa Therapeutics Alternatives Erasca Alternatives Mereo BioPharma Group Alternatives SNDL Alternatives Entrada Therapeutics Alternatives SIGA Technologies Alternatives Eton Pharmaceuticals Alternatives Kamada Alternatives Allogene Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRS Stock Free CHRS Stock Alerts